{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:57:09Z","timestamp":1791021429849,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.clgc.2019.05.010","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T20:03:48Z","timestamp":1559333028000},"page":"356-365.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3553-6142","authenticated-orcid":false,"given":"Ruchitbhai","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Botteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn T.","family":"Solem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.05.010_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","volume":"7","author":"Chow","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2019.05.010_bib2","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2019.05.010_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semcancer.2012.06.004","article-title":"Current and future systemic treatments for renal cell carcinoma","volume":"23","author":"Fisher","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clgc.2019.05.010_bib4","doi-asserted-by":"crossref","first-page":"618","DOI":"10.6004\/jnccn.2009.0043","article-title":"NCCN clinical practice guidelines in oncology: kidney cancer","volume":"7","author":"Motzer","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2019.05.010_bib5","doi-asserted-by":"crossref","first-page":"804","DOI":"10.6004\/jnccn.2017.0100","article-title":"Kidney cancer, version 2.2017, NCCN\u00a0clinical practice guidelines in oncology","volume":"15","author":"Motzer","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2019.05.010_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-065X.2011.01012.x","article-title":"Molecular mechanisms of T-cell tolerance","volume":"241","author":"Nurieva","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clgc.2019.05.010_bib7","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clgc.2019.05.010_bib8","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2019.05.010_bib9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.05.010_bib10","doi-asserted-by":"crossref","first-page":"e000147","DOI":"10.1136\/esmoopen-2016-000147","article-title":"Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)","volume":"2","author":"Salvatore","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.clgc.2019.05.010_bib11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1634\/theoncologist.2017-0257","article-title":"Individual trade-offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma","volume":"23","author":"Postmus","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2019.05.010_bib12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cpt.332","article-title":"Incorporating patient preferences into drug development and regulatory decision making: results from a quantitative pilot study with cancer patients, carers, and regulators","volume":"99","author":"Postmus","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clgc.2019.05.010_bib13","series-title":"Plan for issuance of patient-focused drug development guidance under 21st Century Cures Act Title III Section 3002","year":"2017"},{"key":"10.1016\/j.clgc.2019.05.010_bib14","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.1989.7.1.36","article-title":"Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis","volume":"7","author":"Goldhirsch","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib16","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1200\/JCO.1986.4.12.1772","article-title":"A\u00a0new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer","volume":"4","author":"Gelber","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib17","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1002\/cncr.30662","article-title":"Q-TWiST: what really matters to the cancer patient?","volume":"123","author":"Husson","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.05.010_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/11535290-000000000-00000","article-title":"Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma","volume":"28","author":"Zbrozek","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clgc.2019.05.010_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/14737167.2018.1434414","article-title":"Systematic review and benchmarking of quality-adjusted time without symptoms or toxicity (Q-TWiST) in oncology","volume":"18","author":"Solem","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clgc.2019.05.010_bib20","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bjc.2012.149","article-title":"Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-alpha","volume":"106","author":"Patil","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2019.05.010_bib21","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/cncr.29888","article-title":"Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma","volume":"122","author":"Beaumont","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.05.010_bib22","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.eururo.2017.02.010","article-title":"CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.05.010_bib23","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/jnci\/djq310","article-title":"Improved endpoints for cancer immunotherapy trials","volume":"102","author":"Hoos","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2019.05.010_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11136-005-1579-7","article-title":"Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data","volume":"15","author":"Revicki","year":"2006","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clgc.2019.05.010_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/00031305.1995.10476135","article-title":"Comparing treatments using quality-adjusted survival: the Q-TWiST method","volume":"49","author":"Gelber","year":"1995","journal-title":"Am Statist"},{"key":"10.1016\/j.clgc.2019.05.010_bib26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib27","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2051-1426-1-18","article-title":"Statistical issues and challenges in immuno-oncology","volume":"1","author":"Chen","year":"2013","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.clgc.2019.05.010_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.urolonc.2014.10.009","article-title":"Immunotherapy for castration-resistant prostate cancer: progress and new paradigms","volume":"33","author":"Quinn","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib30","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.05.010_bib31","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2013.33.e280","article-title":"Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer","author":"Chow","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"Suppl 8","key":"10.1016\/j.clgc.2019.05.010_bib32","doi-asserted-by":"crossref","first-page":"viii15","DOI":"10.1093\/annonc\/mds258","article-title":"How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma","volume":"23","author":"Wolchok","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1524-4733.2007.00183.x","article-title":"Development and validation of a scale to measure disease-related symptoms of kidney cancer","volume":"10","author":"Cella","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.clgc.2019.05.010_bib34","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1758834016679942","article-title":"Nivolumab in renal cell carcinoma: latest evidence and clinical potential","volume":"9","author":"Mazza","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.clgc.2019.05.010_bib36","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1200\/JCO.2018.36.15_suppl.4556","article-title":"Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203)","volume":"36","author":"Chen","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib37","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1200\/JCO.2008.19.9836","article-title":"Metastatic renal cell carcinoma: many treatment options, one patient","volume":"27","author":"Rini","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1758834014567470","article-title":"Nivolumab in NSCLC: latest evidence and clinical potential","volume":"7","author":"Sundar","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib39","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib40","first-page":"3","article-title":"Current approaches, challenges and future directions for monitoring treatment response in prostate cancer","volume":"5","author":"Wallace","year":"2014","journal-title":"J\u00a0Cancer"},{"issue":"6 Suppl","key":"10.1016\/j.clgc.2019.05.010_bib41","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2017.35.6_suppl.488","article-title":"Is RECIST-defined progression free-survival a meaningful endpoint in the era of immunotherapy?","volume":"35","author":"Johal","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib42","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamaoncol.2016.0775","article-title":"Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial","volume":"2","author":"George","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib43","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrclinonc.2015.29","article-title":"Patient-reported outcomes as end points and outcome indicators in solid tumours","volume":"12","author":"Secord","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib44","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/bjc.2011.589","article-title":"Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma","volume":"106","author":"Cella","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2019.05.010_bib45","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.05.010_bib46","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/cncr.30661","article-title":"REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma: a quality-adjusted time without symptoms of progression or toxicity analysis","volume":"123","author":"Berry","year":"2017","journal-title":"Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731930148X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731930148X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:32:09Z","timestamp":1761564729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876731930148X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S155876731930148X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.05.010","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}